Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Informed ecological rewiring of gut microbiome for dysbiosis-associated disorders

Project description

Precision microbiome therapy for dysbiosis-associated disorders

Dysbiosis-associated disorders are caused by disruption of the gut microbiome. However, existing therapies are untargeted and ineffective. The ERC-funded MicroRestore project aims to prove that metagenome-informed ecological rewiring of the gut microbiome holds promise as a therapy for dysbiosis-associated disorders by demonstrating efficacy in post-infectious irritable bowel syndrome (PI-IBS). The project will include observational studies, in silico, in vitro studies, and in vivo studies. It will establish target microbe populations in patients, simulate recovery strategies, and assess microbial therapies using gut simulators or mice. If successful, the therapy will be validated using a randomised study on PI-IBS patients. The goal is to take microbiome medicine forward from the bench to the bedside.

Objective

Gut microbiome disruption contributes to the so-called “dysbiosis-associated disorders”. Although the interindividual variability and plasticity of microbiome support its precise modulation, to date only untargeted treatments are available, mostly with inconsistent results. My preliminary data hint that tailored microbial therapy, guided by microbiome profiling, may improve post-infectious irritable bowel syndrome (PI-IBS), a common but understudied dysbiosis-associated disease.
MicroRestore aims to prove that metagenome-informed ecological rewiring of gut microbiome can improve dysbiosis-associated disorders, using PI-IBS as disease model. I will apply a comprehensive multimodal approach, moving from observational/in-silico data to experimental in-vitro and in-vivo outputs to clinical validation. In Aim1 I will assess the microbiome of PI-IBS patients, identify target taxa by machine learning, build ecological models to predict recovery strategies (e.g. competition, pathobiont suppression, antagonism, mutualism, symbiont growth, full rewiring). Based on such strategies, in Aim2 I will use a gut simulator to test the effect of microbial therapeutics (antibiotics, prebiotics, microbial consortia, targeted fecal transplant) on patient microbiota, narrowing them down to build an ecological framework for microbial restoration. In parallel I will rig up known PI-IBS mouse models by colonizing germ-free and C. rodentium-infected mice with patient microbiota or target taxa. Then I will test down-selected interventions in such mice. In Aim3 I will validate this metagenome-informed, targeted framework for microbiome rewiring in a randomized trial of PI-IBS patients. My strategy may offer a notable clinical benefit to PI-IBS and other dysbiosis-associated diseases. By developing an innovative ecological approach for microbial therapy, MicroRestore will promote a microbiome-based precision medicine, filling the knowledge gap between science and clinical practice in this field

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC - HORIZON ERC Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2025-STG

See all projects funded under this call

Host institution

UNIVERSITA CATTOLICA DEL SACRO CUORE
Net EU contribution
€ 1 499 557,00
Address
LARGO GEMELLI 1
20123 MILANO
Italy
Region
Centro (IT) Lazio Roma
Activity type
Higher or Secondary Education Establishments
Links
Total cost
€ 1 499 557,50

Beneficiaries (1)